META MATERIALS INC (MMAT)

US59134N3026 - Common Stock

3.16  +0.15 (+4.98%)

Premarket: 3.02 -0.14 (-4.43%)

Fundamental Rating

2

Taking everything into account, MMAT scores 2 out of 10 in our fundamental rating. MMAT was compared to 107 industry peers in the Semiconductors & Semiconductor Equipment industry. Both the profitability and financial health of MMAT have multiple concerns. While showing a medium growth rate, MMAT is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

In the past year MMAT has reported negative net income.
In the past year MMAT has reported a negative cash flow from operations.
MMAT had negative earnings in each of the past 5 years.
In the past 5 years MMAT always reported negative operating cash flow.

1.2 Ratios

MMAT has a worse Return On Assets (-721.07%) than 97.17% of its industry peers.
Looking at the Return On Equity, with a value of -1815.36%, MMAT is doing worse than 93.40% of the companies in the same industry.
Industry RankSector Rank
ROA -721.07%
ROE -1815.36%
ROIC N/A
ROA(3y)-253.79%
ROA(5y)-164.98%
ROE(3y)-621.15%
ROE(5y)-406.01%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 58.98%, MMAT belongs to the best of the industry, outperforming 81.13% of the companies in the same industry.
MMAT's Gross Margin has improved in the last couple of years.
MMAT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y9.45%

2

2. Health

2.1 Basic Checks

MMAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MMAT has been reduced compared to 1 year ago.
Compared to 5 years ago, MMAT has less shares outstanding
MMAT has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -18.49, we must say that MMAT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -18.49, MMAT is not doing good in the industry: 84.91% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.13 indicates that MMAT is not too dependend on debt financing.
MMAT has a Debt to Equity ratio of 0.13. This is comparable to the rest of the industry: MMAT outperforms 54.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -18.49
ROIC/WACCN/A
WACC10.42%

2.3 Liquidity

A Current Ratio of 0.74 indicates that MMAT may have some problems paying its short term obligations.
With a Current ratio value of 0.74, MMAT is not doing good in the industry: 94.34% of the companies in the same industry are doing better.
A Quick Ratio of 0.73 indicates that MMAT may have some problems paying its short term obligations.
MMAT has a Quick ratio of 0.73. This is amonst the worse of the industry: MMAT underperforms 89.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.74
Quick Ratio 0.73

6

3. Growth

3.1 Past

MMAT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -5779.16%.
Looking at the last year, MMAT shows a very negative growth in Revenue. The Revenue has decreased by -21.93% in the last year.
The Revenue has been growing by 44.15% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5779.16%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-33374.97%
Revenue 1Y (TTM)-21.93%
Revenue growth 3Y247.39%
Revenue growth 5Y44.15%
Revenue growth Q2Q60.19%

3.2 Future

MMAT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.20% yearly.
Based on estimates for the next years, MMAT will show a very strong growth in Revenue. The Revenue will grow by 175.50% on average per year.
EPS Next Y-5733.33%
EPS Next 2Y39.94%
EPS Next 3Y34.2%
EPS Next 5YN/A
Revenue Next Year312.22%
Revenue Next 2Y289.54%
Revenue Next 3Y175.51%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MMAT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MMAT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MMAT's earnings are expected to grow with 34.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.94%
EPS Next 3Y34.2%

0

5. Dividend

5.1 Amount

MMAT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

META MATERIALS INC

NASDAQ:MMAT (4/26/2024, 7:04:05 PM)

Premarket: 3.02 -0.14 (-4.43%)

3.16

+0.15 (+4.98%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap19.94M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -721.07%
ROE -1815.36%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 58.98%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.74
Quick Ratio 0.73
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-5779.16%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-5733.33%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-21.93%
Revenue growth 3Y247.39%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y